ARUP CLARISPECT™ Supports Highly Sensitive Detection for Rare Residual Malignant Populations

Join our presentation at the 68th ASH® Annual Meeting and Exposition

4:15–4:30 p.m. | Sunday, December 13, 2026
68th ASH® Annual Meeting and Exposition 
Hall J, Corporate Presentation Theater 3
Ernest N. Morial Convention Center, New Orleans

Add this event to your calendar.

ARUP CLARISPECT transforms MRD assessment:

  • Highly sensitive detection
  • Results in 1–3 days
  • No baseline sample required
  • Minimal specimen volume requirements
  • Reduced cost

Minimal residual disease (MRD) status has emerged as one of the most powerful prognostic indicators across hematologic malignancies, and highly accurate MRD assessment is critical for disease monitoring, response assessment, clinical trial design, and therapeutic decision-making. ARUP CLARISPECT, the first clinical high-parameter spectral flow assay available from a reference laboratory in the United States, provides a more comprehensive immunophenotypic characterization and supports highly sensitive detection of rare residual malignant populations. CLARISPECT is the latest development from ARUP Laboratories, a long-standing leader in advancing laboratory medicine for hematologic disorders. Explore how our innovative assays and world-class expertise empower clinicians with better insights to treat disease.

Speakers

Madhu P. Menon, MD, PhD, FCAP, FASCP

Head of Clinical Operations for Hematopathology, ARUP Laboratories 

David Ng, MD, FCAP

Medical Director, Hematopathology, Hematologic Flow Cytometry, Applied Artificial Intelligence and Bioinformatics, ARUP Laboratories 

Visit ARUP at Booth #2422

Connect with our medical and laboratory experts to discover more about the clinical benefits of spectral flow cytometry.

Request more information.

 

Not an official event of the 68th ASH® Annual Meeting and Exposition. This session is not sponsored or endorsed by ASH. Not CME-accredited.